Details of Disease

General Information of Disease (ID: DISHVCOZ)

Disease Name Brain metastases
Disease Class 2D50-2E2Z: Metastatic tumour
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISHVCOZ: Brain metastases
ICD Code
ICD-11
ICD-11: 2D50
ICD-10
ICD-10: C79.3
ICD-9
ICD-9: 198.3
Expand ICD-11
'2D50
Expand ICD-10
'C79.3
Expand ICD-9
198.3

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Bevacizumab DMSD1UN Approved Monoclonal antibody [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Onzeald DM4P72R Phase 3 NA [2]
Trans-sodium crocetinate DMQOQBL Phase 3 Small molecular drug [2]
ANG1005 DMV5ENT Phase 2 NA [2]
Avastin DM861TP Phase 2 NA [2]
DM-CHOC-PEN DMBC7HZ Phase 2 NA [2]
GRN1005 DMR34X5 Phase 2 NA [3]
KD019 DMEFW3G Phase 2 Small molecular drug [2]
TPI 287 DM3I5NU Phase 2 NA [2]
Verubulin DMBQC3L Phase 2 Small molecular drug [4]
2X-111 DMMK4J7 Phase 1 NA [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Drug(s)
This Disease is Treated as An Indication in 1 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
PMID28270010-Compound-Figure21-b DM6IYAT Patented Small molecular drug [5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01497665) GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.